Reuters: Global Markets: Biogen says Lou Gehrig's disease drug fails in trial

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Biogen says Lou Gehrig's disease drug fails in trial Jan 3rd 2013, 14:39 Tweet Share this Email Print Related News U.S. approves J&J drug-resistant tuberculosis treatment Mon, Dec 31 2012 Italian Nobel scientist Montalcini dies at 103 Sun, Dec 30 2012 Ex-SAC fund manager indicted in insider trading scheme Fri, Dec 21 2012 Merck cholesterol drug fails; risks seen Thu, Dec 20 2012 Medicines Co skin infection antibiotic meets trial goal Thu, Dec 20 2012 Analysis & Opinion The Watanabes are coming Essential reading: Charities battle Obama over taxes, and more Related Topics Health » Hot Stocks » Asian Markets » Investing and Taxes Simplified » A pedestrian passes the sign outside the headquarters of Biogen Idec Inc. in Cambridge, Massachusetts June 18, 2008. Credit: Reuters/Brian Snyder Thu Jan 3, 2013 9:39am EST (Reuters) - An experimental drug to combat amyotrophic lateral sclerosis, commonly called Lou Gehrig's disease in the United States, failed to work in an important trial and Biogen Idec said it would stop development of the treatment. The drug, dexpramipexole, had shown promise and seemed to work against ALS in a mid-stage clinical trial in 2011. Biogen shares fell 6 percent in premarket trading on Thursday. ALS is a disease of nerve cells in the brain and spinal cord that affects about 30,000 Americans, according to the ALS Association. About 5,600 Americans are diagnosed with the disease each year. American baseball player Henry Louis "Lou" Gehrig died of the disease in 1941. There is currently only one drug that is used to help people with ALS - Rilutek, or riluzole, made by Sanofi. It has been shown to prolong the life of people with ALS, who have a life expectancy of two to five years after diagnosis. The news was an uncommon blow for a company that has excelled in recent years and could push shares down about 10 percent, Mark Schoenebaum, a biotech analyst at ISI Group, said in an early research note. He said analysts had estimated sales for the drug in 2016 of about $350 million - or about 4 percent of Biogen revenue. The late-stage dexpramipexole trial, which was called Empower and enrolled 943 people with ALS at 81 sites in 11 countries, did not show that the drug increased the ability of people with the disease to function or improved their survival rates. "We share the disappointment of members of the ALS community, who had hoped that dexpramipexole would offer a meaningful new treatment option," Biogen Executive Vice President of Research and Development Douglas Williams said in a statement. The company said it would continue to work on potential treatments for the disease. (Reporting by Caroline Humer in New York and Esha Dey in Bangalore; Editing by Roshni Menon, Nick Zieminski and John Wallace) Investing and Taxes Simplified Related Quotes and News Company Price Related News Tweet this Link this Share this Digg this Email Reprints We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/ Comments (0) Be the first to comment on reuters.com. Add yours using the box above.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions